Journal
CANCER LETTERS
Volume 359, Issue 1, Pages 1-8Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.12.050
Keywords
BRAF; MEK; c-KIT; PI3K/Akt/mTOR; CTLA-4; PD-1/L1
Categories
Funding
- National Nature Science Foundation of China [81372872, 81402215, 81320108022]
- University Cancer Foundation via the Sister Institution Network Fund (SINF)
Ask authors/readers for more resources
Melanoma is the most deadly cutaneous cancer primarily derived from melanocytes with a poor prognosis in advanced stage. The therapy regimen for early stage melanoma patients is surgical resection with adjuvant IFN-alpha-2b therapy. For metastatic lesions, standard chemotherapy such as dacarbazine (DTIC) has not achieved a satisfying response rate. Therefore, new approaches to manage this deadly disease are highly expected to enhance the cure rate and to extend clinical benefits to patients with unresectable melanoma. Fortunately, the targeted therapeutic drugs and immunotherapy such as vemurafenib, dabrafenib, ipilimumab, and trametinib have shown their special advantage in the treatment of advanced melanoma. This article is to overview the advances in targeted therapy for unresectable melanoma patients. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available